IP Library Granted Patent US 7,608,690
Granted Patent B2
US 7,608,690 · App. 11/006,154 · Granted Oct 27, 2009

IL-B30 antibodies

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,608,690
App. No.
11/006,154
Granted
Oct 27, 2009
Kind
B2
Abstract

Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.

Claims (37)

1. A recombinant antibody or antigen binding fragment thereof that binds to a polypeptide having the amino acid sequence of SEQ ID NO: 2.

2. The antigen binding fragment of claim 1 selected from:

a) a Fab fragment;

b) a Fab 2 fragment; or

c) a single chain antibody.

3. The recombinant antibody or antigen binding fragment of claim 1 , which binds said polypeptide with an affinity of at least 100 nM.

4. The recombinant antibody or antigen binding fragment of claim 1 , which binds said polypeptide with an affinity of at least 30 nM.

5. The recombinant antibody or antigen binding fragment of claim 1 , which binds said polypeptide with an affinity of at least 10 nM.

6. The recombinant antibody or antigen binding fragment of claim 1 , which binds said polypeptide with an affinity of at least 3 nM.

7. The recombinant antibody or antigen binding fragment of claim 1 , which binds said polypeptide with a dissociation constant (K D ) of at least 3 μM.

8. The recombinant antibody of claim 1 , wherein said antibody is a full length antibody.

9. The recombinant antibody of claim 1 , wherein said antibody is a monoclonal antibody.

10. The recombinant antibody of claim 1 , wherein said antibody is an antagonist antibody.

11. The recombinant antibody or antigen binding fragment of claim 1 , comprising a detectable label.

12. The recombinant antibody or antigen binding fragment of claim 11 , wherein the detectable label is a radioactive or fluorescent label.

13. A sterile composition comprising the recombinant antibody or antigen binding fragment of claim 1 .

14. The sterile composition of claim 13 , wherein said sterile composition comprises an aqueous carrier.

15. The sterile composition of claim 14 , wherein said aqueous carrier comprises one or more of water, saline, or buffer.

16. The recombinant antibody or antigen binding fragment of claim 1 , which binds to a polypeptide having the amino acid sequence of residues 1-168 of SEQ ID NO: 2.

17. A monoclonal antibody or antigen binding fragment thereof, that binds to a polypeptide having the amino acid sequence of SEQ ID NO:2.

18. The antigen binding fragment of claim 17 selected from:

a) a Fab fragment;

b) a Fab 2 fragment; or

c) a single chain antibody.

19. The monoclonal antibody of claim 17 , wherein said antibody is a full length antibody.

20. The monoclonal antibody of claim 17 , wherein said antibody is an antagonist antibody.

21. The monoclonal antibody or antigen binding fragment of claim 17 , comprising a detectable label.

22. The monoclonal antibody or antigen binding fragment of claim 21 , wherein the detectable label is a radioactive or fluorescent label.

23. The monoclonal antibody or antigen binding fragment of claim 17 , which binds said polypeptide with an affinity of at least 100 nM.

24. The monoclonal antibody or antigen binding fragment of claim 17 , which binds said polypeptide with an affinity of at least 30 nM.

25. The monoclonal antibody or antigen binding fragment of claim 17 , which binds said polypeptide with an affinity of at least 10 nM.

26. The monoclonal antibody or antigen binding fragment of claim 17 , which binds said polypeptide with an affinity of at least 3 nM.

27. The monoclonal antibody or antigen binding fragment of claim 17 , which binds said polypeptide with a dissociation constant (K D ) of at least 3 μM.

28. A sterile composition comprising the monoclonal antibody or antigen binding fragment of claim 17 .

29. The sterile composition of claim 28 , wherein said sterile composition comprises an aqueous carrier.

30. The sterile composition of claim 29 , wherein said aqueous carrier comprises one or more of water, saline, or buffer.

31. The monoclonal antibody or antigen binding fragment of claim 17 , which binds to a polypeptide having the amino acid sequence of residues 1-168 of SEQ ID NO: 2.

Assignments (1)
CHANGE OF NAME Recorded Aug 30, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028884/0151 →